中华放射肿瘤学杂志
中華放射腫瘤學雜誌
중화방사종류학잡지
CHINESE JOURNAL OF RADIATION ONCOLOGY
2010年
4期
302-305
,共4页
张瑾熔%杨蛟%吕茵%阿衣古丽·哈热
張瑾鎔%楊蛟%呂茵%阿衣古麗·哈熱
장근용%양교%려인%아의고려·합열
肿瘤复发,食管%肿瘤复发,术后%放射疗法%预后
腫瘤複髮,食管%腫瘤複髮,術後%放射療法%預後
종류복발,식관%종류복발,술후%방사요법%예후
Neoplasm recurrence,Esophageal%Neoplasm recurrence,postoperative%Radiotherapy%Prognosis
目的 探讨食管癌术后局部复发转移的放疗疗效和预后影响因素.方法 回顾性分析食管癌术后局部复发转移行放疗的91例患者资料,术后复发时间为1~35个月,中位数为11.1个月.吻合口复发4例,纵隔淋巴结转移+吻合口复发6例;腹腔淋巴结转移4例,锁骨上淋巴结转移20例,纵隔淋巴结转移34例,锁骨上区+纵隔淋巴结转移23例.常规放疗56例,三维适形放疗35例,剂量50~70 Gy.68例联合化疗1~4个周期.结果 随访率为95%.1、2、3年生存率分别为52%、20%和14%.Logrank单因素分析显示术后复发时间、术后临床分期、放疗剂量、近期疗效、术后T分期、术后N分期与预后相关(P=0.001、0.000、0.001、0.000、0.028、0.003).Cox多因素分析结果显示术后复发时间、术后临床分期、放疗剂量、近期疗效是独立预后因素(P=0.014、0.006、0.009、0.000).结论 食管癌术后局部复发转移患者放疗可以延长部分患者生存时间,术后复发时间长、术后分期早、放疗后近期疗效好、放疗总剂量≥60 Gy者预后较好.
目的 探討食管癌術後跼部複髮轉移的放療療效和預後影響因素.方法 迴顧性分析食管癌術後跼部複髮轉移行放療的91例患者資料,術後複髮時間為1~35箇月,中位數為11.1箇月.吻閤口複髮4例,縱隔淋巴結轉移+吻閤口複髮6例;腹腔淋巴結轉移4例,鎖骨上淋巴結轉移20例,縱隔淋巴結轉移34例,鎖骨上區+縱隔淋巴結轉移23例.常規放療56例,三維適形放療35例,劑量50~70 Gy.68例聯閤化療1~4箇週期.結果 隨訪率為95%.1、2、3年生存率分彆為52%、20%和14%.Logrank單因素分析顯示術後複髮時間、術後臨床分期、放療劑量、近期療效、術後T分期、術後N分期與預後相關(P=0.001、0.000、0.001、0.000、0.028、0.003).Cox多因素分析結果顯示術後複髮時間、術後臨床分期、放療劑量、近期療效是獨立預後因素(P=0.014、0.006、0.009、0.000).結論 食管癌術後跼部複髮轉移患者放療可以延長部分患者生存時間,術後複髮時間長、術後分期早、放療後近期療效好、放療總劑量≥60 Gy者預後較好.
목적 탐토식관암술후국부복발전이적방료료효화예후영향인소.방법 회고성분석식관암술후국부복발전이행방료적91례환자자료,술후복발시간위1~35개월,중위수위11.1개월.문합구복발4례,종격림파결전이+문합구복발6례;복강림파결전이4례,쇄골상림파결전이20례,종격림파결전이34례,쇄골상구+종격림파결전이23례.상규방료56례,삼유괄형방료35례,제량50~70 Gy.68례연합화료1~4개주기.결과 수방솔위95%.1、2、3년생존솔분별위52%、20%화14%.Logrank단인소분석현시술후복발시간、술후림상분기、방료제량、근기료효、술후T분기、술후N분기여예후상관(P=0.001、0.000、0.001、0.000、0.028、0.003).Cox다인소분석결과현시술후복발시간、술후림상분기、방료제량、근기료효시독립예후인소(P=0.014、0.006、0.009、0.000).결론 식관암술후국부복발전이환자방료가이연장부분환자생존시간,술후복발시간장、술후분기조、방료후근기료효호、방료총제량≥60 Gy자예후교호.
Objective To study the effect of radiotherapy and prognostic factors for patients with post-operative loco-regional recurrence of esophageal carcinoma. Methods From 2000 to 2005,91 patients with esophageal carcinoma who developed post-operative loco-regional recurrence were analyzed retrospectively. The interval between surgery and recurrence was 1 -35 months, with a median interval of 11.1 months. There were 4 patients with anastomosis relapse, 6 with anastomosis and mediastinal lymph nodes relapse,4 with abdominal lymph node relapse, 20 with supra-clavicular lymph node relapse, 34 with mediastinal lymph node relapse, and 23 with mediastinal and supra-clavicular lynph node relapse. There were 56 and 35 patients who received conventional and three-dimensional conformal radiation therapy respectively, with a total radiation dose of 50 -70 Gy. Sixty-eight patients received adjuvant chemotherapy.Results The follow-up rate was 95%. The 1-,2-and 3-year overall survival rates were 52%, 20% and 14%, respectively. In univariate analysis, the recurrence time (P = 0. 001), postoperative stage (P =0. 000), radiation dose (P =0. 001) ,overall response rate (P =0. 000) ,T stage (P =0. 028), and N stage (P = 0. 003) were related with prognosis. Multivariate analysis showed that the recurrence time (P =0. 014), postoperative stage (P = 0. 006), radiation dose (P = 0. 009), overall response rate (P = 0. 000)were independent prognostic factors for survival. Conclusions Radiotherapy may improve the survival of esophageal carcinoma patients with postoperative recurrence. Patients with long recurrence-free time, early stage, high response rates, and radiation dose of higher than 60 Gy have better prognosis.